Pulmatrix, Inc.
Pulmatrix, Inc. (PULM): 3 pipeline candidates · ~10 mo cash runway · 5 clinical trials. Updated within the last hour.
BioSniper Score
4-factor signal · derived from public data
10.3 months
D/E 0.25 · 0% dilution
Lead: Phase 2
3 candidates
N/A
N/A
A transparent, data-derived signal for Pulmatrix, Inc.across cash runway, pipeline maturity & breadth, catalyst momentum and clinical/regulatory footprint. Each factor traces to tracked public filings — not an investment recommendation.
Key Financials
Market Cap
$5.4M
Cash
$3.3M
Quarterly Burn
$1.1M
Runway
10.3 mo
Revenue
—
Cash Runway vs Catalysts
Tracked catalysts land within the current projected cash runway.
Pipeline (3 candidates)
Institutional Holdings
Source: SEC Form 13F · as of Mar 2026Institutional holders
13
Total value held
$429K
| Holder | Shares | Value |
|---|---|---|
| renaissance technologies llc | 109,148 | $141K |
| vanguard capital management llc | 67,188 | $87K |
| blackrock, inc. | 54,899 | $71K |
| geode capital management, llc | 44,629 | $58K |
| vanguard fiduciary trust co | 14,715 | $19K |
| jane street group, llc | 14,584 | $19K |
| state street corp | 13,945 | $18K |
| xtx topco ltd | 13,669 | $18K |
| ubs group ag | 23 | $30 |
| farther finance advisors, llc | 7 | $9 |
Showing top 10 of 13 institutional holders of Pulmatrix, Inc.. Sign up for the full 13F holder list and quarter-by-quarter ownership history.
Frequently asked questions
How many drug candidates are in Pulmatrix, Inc.'s pipeline?
Pulmatrix, Inc. (PULM) has 3 pipeline candidates tracked by BioSniper across SEC filings and clinical trial registrations.
What is Pulmatrix, Inc.'s lead drug candidate?
Pulmatrix, Inc.'s most advanced tracked candidate is pur1800 (Phase 1) for acute exacerbations of chronic obstructive pulmonary disease ("AECOPD").
What is Pulmatrix, Inc.'s cash runway?
Based on its most recent reported cash balance and quarterly burn rate, Pulmatrix, Inc. has approximately 10.3 months of cash runway.
What is Pulmatrix, Inc.'s market capitalization?
Pulmatrix, Inc.'s market capitalization is approximately $5.4M.
Who is the CEO of Pulmatrix, Inc.?
Mr. Peter Ludlum CMA, MBA is the chief executive officer of Pulmatrix, Inc. (PULM).
Get the full picture on Pulmatrix, Inc.
Deep pipeline analysis, financial trends, AI-powered investment signals, and real-time catalyst alerts.